Response to 2020 American College of Rheumatology Guideline for the Management of Gout

Peter E Lipsky; N Lawrence Edwards; Theodore R Fields; Robert T Keenan; Brian F Mandell; Naomi Schlesinger

doi:10.1002/acr.24379

Response to 2020 American College of Rheumatology Guideline for the Management of Gout

Peter E Lipsky, N Lawrence Edwards, Theodore R Fields, Robert T Keenan, Brian F Mandell, Naomi Schlesinger

New Brunswick

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

We reviewed the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout with interest. First, we want to commend the committee for the excellent job they did in updating the guidelines. We noted the commitment to evidence- based medicine and also that the indications for starting urate-lowering therapy (ULT) have been expanded to consider patients with infrequent gout flares or a first gout flare if they also have moderate to severe chronic kidney disease (CKD stage ≥ 3), marked hyperuricemia (serum urate (SU) > 9 mg/dl) or kidney stones.

Original language	English (US)
Journal	Arthritis Care and Research
DOIs	https://doi.org/10.1002/acr.24379
State	E-pub ahead of print - Jul 23 2020

Access to Document

10.1002/acr.24379

Cite this

@article{7977303fc49d4982930f9d23c59bf4bc,

title = "Response to 2020 American College of Rheumatology Guideline for the Management of Gout",

abstract = "We reviewed the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout with interest. First, we want to commend the committee for the excellent job they did in updating the guidelines. We noted the commitment to evidence- based medicine and also that the indications for starting urate-lowering therapy (ULT) have been expanded to consider patients with infrequent gout flares or a first gout flare if they also have moderate to severe chronic kidney disease (CKD stage ≥ 3), marked hyperuricemia (serum urate (SU) > 9 mg/dl) or kidney stones.",

author = "Lipsky, {Peter E} and Edwards, {N Lawrence} and Fields, {Theodore R} and Keenan, {Robert T} and Mandell, {Brian F} and Naomi Schlesinger",

year = "2020",

month = jul,

day = "23",

doi = "10.1002/acr.24379",

language = "English (US)",

journal = "Arthritis Care and Research",

issn = "2151-4658",

}

TY - JOUR

T1 - Response to 2020 American College of Rheumatology Guideline for the Management of Gout

AU - Lipsky, Peter E

AU - Edwards, N Lawrence

AU - Fields, Theodore R

AU - Keenan, Robert T

AU - Mandell, Brian F

AU - Schlesinger, Naomi

PY - 2020/7/23

Y1 - 2020/7/23

N2 - We reviewed the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout with interest. First, we want to commend the committee for the excellent job they did in updating the guidelines. We noted the commitment to evidence- based medicine and also that the indications for starting urate-lowering therapy (ULT) have been expanded to consider patients with infrequent gout flares or a first gout flare if they also have moderate to severe chronic kidney disease (CKD stage ≥ 3), marked hyperuricemia (serum urate (SU) > 9 mg/dl) or kidney stones.

AB - We reviewed the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout with interest. First, we want to commend the committee for the excellent job they did in updating the guidelines. We noted the commitment to evidence- based medicine and also that the indications for starting urate-lowering therapy (ULT) have been expanded to consider patients with infrequent gout flares or a first gout flare if they also have moderate to severe chronic kidney disease (CKD stage ≥ 3), marked hyperuricemia (serum urate (SU) > 9 mg/dl) or kidney stones.

U2 - 10.1002/acr.24379

DO - 10.1002/acr.24379

M3 - Article

C2 - 32702211

SN - 2151-4658

JO - Arthritis Care and Research

JF - Arthritis Care and Research

ER -

Response to 2020 American College of Rheumatology Guideline for the Management of Gout

Abstract

Access to Document

Fingerprint

Cite this